Literature DB >> 20437929

Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey.

Hugh J McMillan1, Craig Campbell, Jean K Mah.   

Abstract

BACKGROUND: Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood.
METHOD: To assess the current care of paediatric DMD patients in Canada, a questionnaire was mailed to 17 physicians who were members of the Canadian paediatric neuromuscular group. Areas of enquiry included; 1) multidisciplinary team composition; 2) means of DMD diagnosis; 3) corticosteroid use; surveillance and management for: 4) orthopaedic, 5) respiratory and 6) cardiac complications and 7) health maintenance (nutrition & immunizations).
RESULTS: Completed surveys were returned by 14/17 (82%) of physicians. Twelve respondents followed DMD patients. All centres had multidisciplinary teams, including respirology (11/12), child neurology or physiatry (11), physiotherapy (9), occupational therapy (9) and orthopaedic surgery (7). Deflazacort 0.9 mg/kg/d was used at all centres, which was continued after loss of independent ambulation (11), along with routine calcium and vitamin D supplementation (10). Night splints were prescribed at all centres. Routine surveillance studies included pulmonary function testing (11), sleep studies (10), EKG/echocardiogram (10), bone density (DEXA) scans (10), spine radiography (9), and dietician referral (4).
CONCLUSION: Paediatric DMD patients are receiving relatively consistent care in multidisciplinary clinics across Canada, in accordance with recommended guidelines for DMD.

Entities:  

Mesh:

Year:  2010        PMID: 20437929     DOI: 10.1017/s0317167100009926

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  11 in total

1.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

2.  The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.

Authors:  J Ma; H J McMillan; G Karagüzel; C Goodin; J Wasson; M A Matzinger; P DesClouds; D Cram; M Page; V N Konji; B Lentle; L M Ward
Journal:  Osteoporos Int       Date:  2016-10-24       Impact factor: 4.507

3.  The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Authors:  Laura C McAdam; Amanda L Mayo; Benjamin A Alman; W Douglas Biggar
Journal:  Acta Myol       Date:  2012-05

Review 4.  The management of osteoporosis in children.

Authors:  L M Ward; V N Konji; J Ma
Journal:  Osteoporos Int       Date:  2016-04-28       Impact factor: 4.507

5.  Cancer risk among patients with hereditary muscular dystrophies: a population-based study in Taiwan, 1997-2009.

Authors:  Gen-Min Lin; Yi-Hwei Li
Journal:  Chin J Cancer       Date:  2014-01-02

6.  Trends in steroid therapy for Duchenne muscular dystrophy in Japan.

Authors:  Fumi Takeuchi; Hirofumi Komaki; Harumasa Nakamura; Naohiro Yonemoto; Kousuke Kashiwabara; En Kimura; Shin'ichi Takeda
Journal:  Muscle Nerve       Date:  2016-07-14       Impact factor: 3.217

7.  The effect of wearing night splints for one year on the standing motor function of patients with Duchenne muscular dystrophy.

Authors:  Hitomi Nishizawa; Ayumi Matsukiyo; Naoko Shiba; Masayoshi Koinuma; Akinori Nakamura
Journal:  J Phys Ther Sci       Date:  2018-04-20

8.  The relationship of bone mineral density and vitamin D levels with steroid use and ambulation in patients with Duchenne muscular dystrophy.

Authors:  Filiz Meryem Sertpoyraz; Bedile İrem Tiftikçioğlu
Journal:  Turk J Phys Med Rehabil       Date:  2019-08-20

Review 9.  Current and emerging treatment strategies for Duchenne muscular dystrophy.

Authors:  Jean K Mah
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-22       Impact factor: 2.570

10.  A Pilot Survey Study of Adherence to Care Considerations for Duchenne Muscular Dystrophy.

Authors:  Kristin Conway; Christina Trout; Christina Westfield; Deborah Fox; Shree Pandya
Journal:  PLoS Curr       Date:  2018-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.